A nonrandomized follow-up comparison between standard axillary node dissection and sentinel node biopsy in breast cancer

详细信息    查看全文

• 作者：Peter Konstantiniuk ; Peter Schrenk ; Rol ; Reitsamer ; Roswitha Koeberle-Wuehrer ; Christoph Tausch ; Sebastian Roka ; Otto Riedl ; Sabine Poestlberger ; Dieter Hecke ; Michael Janauer ; Anton Haid
• 关键词：Breast cancer ; Sentinel node biopsy ; Follow-up ; Recurrences ; Disease-free survival ; Overall survival
• 刊名：The Breast
• 出版年：2007
• 出版时间：October 2007
• 年：2007
• 卷：16
• 期：5
• 页码：520-526
• 全文大小：197 K

文摘

In many countries sentinel node biopsy (SNB) has become the standard of care in breast cancer based on a large number of observational studies but without results from prospective randomized trials. The goal of our study was to evaluate the oncological safety of the SNB in breast cancer in a multicenter, nonrandomized setting with comparable groups.

Patients and methods

Between 1996/05 and 2004/11, 2942 patients from 14 departments in Austria with unicentric, unilateral, invasive disease without neoadjuvant therapy were collected in a database. The recommendations of the Austrian Sentinel Node Study Group were to complete a training period (phase I) with 50 cases of SNB followed by axillary lymph node dissection (ALND) to prove a detection rate of 90 % and a false-negative rate of 5 % . In the executing period (phase II), SNB was followed by ALND only if the sentinel node (SN) contained metastases. We compared the results on disease-free survival, local recurrence rates, distant recurrence rates and overall survival of both groups. Cases from phases I and II generated groups I (n=671) and 2 (n=2271 cases), respectively.

Results

Overall mean follow-up time: 34.41 months